Numerous studies have demonstrated the anti-cancer activity of butyrate in CRC by influencing various signal pathways, including the NRP-1/VEGF, ERK2/MAPK, Wnt/β-catenin, p53 and epigenetic pathways [330,331,332,333,334]. This evidence concerns the gene TP53 and colorectal carcinoma.